Jim Mullen won a $20M option package when he switched from chairman to the CEO job at Editas — and it's all tied to performance
The last time James Mullen ran a biopharma company, he was roasted by Carl Icahn for drawing tens of millions of dollars in compensation at a time Biogen’s stock was going down.
This time, he’s starting back at the helm with a compensation package tied to success. And it’s a potentially hefty one, for a biotech company.
According to an SEC filing that dropped several days after Mullen moved from chairman of Editas to the CEO post of the gene editing pioneer, Mullen’s employment letter — which we won’t get to see until the 10-K drops — includes options of $20 million in company stock.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.